Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2006

Open Access 01-02-2005 | Research

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia

Authors: Eric M Mortensen, Marcos I Restrepo, Antonio Anzueto, Jacqueline Pugh

Published in: Critical Care | Issue 1/2006

Login to get access

Abstract

Introduction

National clinical practice guidelines have recommended specific empiric antimicrobial regimes for patients with severe community-acquired pneumonia. However, evidence confirming improved mortality with many of these regimes is lacking. Our aim was to determine the association between the empiric use of a β-lactam with fluoroquinolone, compared with other recommended antimicrobial therapies, and mortality in patients hospitalized with severe community-acquired pneumonia.

Methods

A retrospective observational study was conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of community-acquired pneumonia and had a chest X-ray and a discharge ICD-9 diagnosis consistent with this. Subjects were excluded if they received 'comfort measures only' during the admission, had been transferred from another acute care hospital, did not meet criteria for severe pneumonia, or were treated with non-guideline-concordant antibiotics. A multivariable logistic regression model was used to assess the association between 30-day mortality and the use of a β-lactam antibiotic with a fluoroquinolone compared with other guideline-concordant therapies, after adjustment for potential confounders including a propensity score.

Results

Data were abstracted on 172 subjects at the two hospitals. The mean age was 63.5 years (SD 15.0). The population was 88% male; 91% were admitted through the emergency department and 62% were admitted to the intensive care unit within the first 24 hours after admission. Mortality was 19.8% at 30 days. After adjustment for potential confounders the use of a β-lactam with a fluoroquinolone (odds ratio 2.71, 95% confidence interval 1.2 to 6.1) was associated with increased mortality.

Conclusion

The use of initial empiric antimicrobial therapy with a β-lactam and a fluoroquinolone was associated with increased short-term mortality for patients with severe pneumonia in comparison with other guideline-concordant antimicrobial regimes. Further research is needed to determine the range of appropriate empiric antimicrobial therapies for patients with severe community-acquired pneumonia.
Appendix
Available only for authorised users
Literature
1.
Freid VM, Prager K, MacKay AP, Xia H: Health, United States, 2003, With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2003.
2.
Gilbert K, Fine MJ: Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994, 9: 140-152.PubMed
3.
The British Thoracic Society: Guidelines for the management of community-acquired pneumonia in adults admitted to the hospital. Br J Hosp Med 1993, 49: 346-350.
4.
Gialdroni Grassi G, Bianchi L: Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology. Italian Society of Respiratory Medicine. Italian Society of Chemotherapy. Monaldi Arch Chest Dis 1995, 50: 21-27.PubMed
5.
Niederman M, Bass JB, Campbell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sarosi GA, Torres A, Vu VL: Guidelines for the initial management of adult with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993, 148: 1418-1426.CrossRefPubMed
6.
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163: 1730-1754.CrossRefPubMed
7.
Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31: 347-382. 10.1086/313954CrossRefPubMed
8.
British Thoracic Society Standards of Care Committee: BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001,56(Suppl 4):IV1-IV64.
9.
Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000, 7: 371-382.PubMed
10.
Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999, 159: 2562-2572. 10.1001/archinte.159.21.2562CrossRefPubMed
11.
Houck PM, MacLehose RF, Niederman MS, Lowery JK: Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 Western States: 1993, 1995, and 1997. Chest 2001, 119: 1420-1426. 10.1378/chest.119.5.1420CrossRefPubMed
12.
Battleman DS, Callahan M, Thaler HT: Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med 2002, 162: 682-688. 10.1001/archinte.162.6.682CrossRefPubMed
13.
Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161: 1837-1842. 10.1001/archinte.161.15.1837CrossRefPubMed
14.
Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH: Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999, 159: 2576-2580. 10.1001/archinte.159.21.2576CrossRefPubMed
15.
Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36: 389-395. 10.1086/367541CrossRefPubMed
16.
Burgess DS, Lewis JS: Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000, 22: 872-878. 10.1016/S0149-2918(00)80059-4CrossRefPubMed
17.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336: 243-250. 10.1056/NEJM199701233360402CrossRefPubMed
18.
Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278: 2080-2084. 10.1001/jama.278.23.2080CrossRefPubMed
19.
Mortensen EM, Kapoor WN, Chang CC, Fine MJ: Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003, 37: 1617-1624. 10.1086/379712CrossRefPubMed
20.
Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ: Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002, 162: 1059-1064. 10.1001/archinte.162.9.1059CrossRefPubMed
21.
Stone RA, Obrosky DS, Singer DE, Kapoor WN, Fine MJ: Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. Med Care 1995,33(4 Suppl):AS56-AS66.PubMed
22.
Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BH, Leufkens HG, de Boer A: Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004, 57: 1223-1231. 10.1016/j.jclinepi.2004.03.011CrossRefPubMed
23.
Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70: 41-55. 10.2307/2335942CrossRef
24.
Hosmer DW, Lemeshow S: Applied Logistic Regression. New York: John Wiley & Sons; 1989.
25.
Rello J, Catalan M, Diaz E, Bodi M, Alvarez B: Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002, 28: 1030-1035. 10.1007/s00134-002-1325-3CrossRefPubMed
26.
Brown RB, Iannini P, Gross P, Kunkel M: Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003, 123: 1503-1511. 10.1378/chest.123.5.1503CrossRefPubMed
27.
Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al.: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170: 440-444. 10.1164/rccm.200311-1578OCCrossRefPubMed
28.
Mortensen EM, Restrepo M, Anzueto A, Pugh J: Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004, 117: 726-731. 10.1016/j.amjmed.2004.06.028CrossRefPubMed
29.
Malone DC, Shaban HM: Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother 2001, 35: 1180-1185. 10.1345/aph.10283CrossRefPubMed
30.
Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M: Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292: 156-163.PubMed
31.
Labro MT: Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998,41(Suppl B):37-46. 10.1093/jac/41.suppl_2.37CrossRefPubMed
32.
Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, Galovic R, Glojnaric I, Manojlovic Z, Munic V, et al.: Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002, 450: 277-289. 10.1016/S0014-2999(02)02042-3CrossRefPubMed
33.
Culic O, Erakovic V, Parnham MJ: Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001, 429: 209-229. 10.1016/S0014-2999(01)01321-8CrossRefPubMed
34.
Puren AJ, Feldman C, Savage N, Becker PJ, Smith C: Patterns of cytokine expression in community-acquired pneumonia. Chest 1995, 107: 1342-1349.CrossRefPubMed
35.
Bauer TT, Monton C, Torres A, Cabello H, Fillela X, Maldonado A, Nicolas JM, Zavala E: Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000, 55: 46-52. 10.1136/thorax.55.1.46PubMedCentralCrossRefPubMed
36.
Moussa K, Michie HJ, Cree IA, McCafferty AC, Winter JH, Dhillon DP, Stephens S, Brown RA: Phagocyte function and cytokine production in community acquired pneumonia. Thorax 1994, 49: 107-111.PubMedCentralCrossRefPubMed
37.
Ortqvist A, Hedlund J, Wretlind B, Carlstrom A, Kalin M: Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995, 27: 457-462.CrossRefPubMed
38.
Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, et al.: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992, 89: 1551-1557.PubMedCentralCrossRefPubMed
39.
van der Poll T, van Deventer SJ, Hack CE, Wolbink GJ, Aarden LA, Buller HR, ten Cate JW: Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992, 79: 693-698.PubMed
40.
Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FBJ: Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli . Circ Shock 1991, 33: 84-91.PubMed
Metadata
Title
The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia
Authors
Eric M Mortensen
Marcos I Restrepo
Antonio Anzueto
Jacqueline Pugh
Publication date
01-02-2005
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc3934

Other articles of this Issue 1/2006

Critical Care 1/2006 Go to the issue

Journal club critique

PAC-Man: Game over for the pulmonary artery catheter?

Research

A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: a retrospective cohort study

Commentary

Do statins have a role in preventing or treating sepsis?

Review

Bench-to-bedside review: Early tracheostomy in critically ill trauma patients

Research

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

Research

A comparison of transcranial Doppler with near infrared spectroscopy and indocyanine green during hemorrhagic shock: a prospective experimental study